Investigation and validation of CD44vRA as a specific biomarker for rheumatoid arthritis targeted therapy for drug development - efficacy and companion

Benefiting from over 15 years extensive research, this collaboration between MaimoniDex, Mologic Ltd, Ig Innovations and Swansea University Medical School is working to develop a new biomarker for early diagnosis and confirmation of rheumatoid arthritis. MaimoniDex has identified a CDD44 isoform termed CD44vRA as a potential therapeutic target. The collaboration brings together the inventor, commercial diagnostic companies and access to patient samples and seeks to develop this biomarker as diagnostic blood test to aid, early diagnosis, early therapeutic intervention, therapeutic efficacy and clinical development of new therapies